Zyprexa :: Multiple pharmacies comparison.

Eli Lilly is to settle more than 18 000 product liability claims against its lead product, the anti-psychotic drug Zyprexa (olanzapine) for schizophrenia and manic depression. The lawsuits mainly revolve around a warning linking the drug with diabetes not being adequately displayed in the package insert.

Related Results

Injectable ZyprexaZyprexa WarningZyprexa filingZyprexa unveiledTexas depresses Zypr…

A U.S. District Court upheld the patent held by Eli Lilly & Co. on olanzapine (Zyprexa), an antipsychotic drug that accounts for about one-third of Lilly’s revenue; net sales in the United States were $2.4 bill…

Lilly added strong warnings to the label of Zyprexa, its best-selling medicine for schizophrenia, Oct. 5, citing the drug’s tendency to cause weight gain, high blood sugar, high cholesterol and other metabolic problems.
For the first time, Zyprexa’s label now acknowledges that …

FDA is examining whether Eli Lilly & Company provided it with accurate data about the side effects of the antipsychotic drug Zyprexa, a potent medicine that has been linked to weight gain and diabetes, “The New York Ti…

Lilly settled an additional 900 product liability lawsuits involving its top-selling drug, the anti-psychotic Zyprexa.
Lilly has settled roughly 28,500 product liability claims involving Zyprexa over the past two years. In June 2005, the company settled 8,000 claims for $690 million. This past January, it settled more than 18…

The drugmaker Eli Lilly & Co. has agreed to pay up to $500 million to settle approximately 18,000 claims related to its atypical antipsychotic Zyprexa (olanzapine). Most of the claims stated that, before September 2003, the Zyprexa package insert did not adequately display the risk of hyperglycemia and diabetes.

…

Simone Roberts
ZYPREXA (olanzapine) has been found to be more effective than lithium in helping people who suffer from bipolar disorder to remain in remission and prevent relapse into mania, according to a study published in a recent issue of the American Journal of Psychiatry .
The year-long study showed that in the maintenance t…

A former consultant to Eli Lilly & Co. has agreed to pay the drug maker $100,000 to settle complaints that he leaked confidential information about Zyprexa (olanzapine) to a plaintiffs’ attorney. Dr. David Egilman was an expert witness for the plaintiffs in Zyprexa product li…

The Texas Medicaid agency announced that it will not include the atypical antipsychotic Zyprexa (olanzapine) on its preferred drug list. To prescribe Zyprexa to Medicaid patients, physicians will now have to get prior authorization from the agency. Texas, similar to many other states, is facing budget constraints; Zyprexa accounted for $86 million of Texas Medicaid’s $1.9 billion in drug spending last year.

Related Results

…

Eli Lilly and Company would like to inform you of important labeling changes regarding Zyprexa (olanzapine). The Food and Drug Administration (FDA) has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add a Warning statement describing the increased…